is now part of
DeepHealth is excited to announce the expansion of our AI-powered breast health capabilities through the strategic acquisition of iCAD.
2D Detection
First iCAD FDA cleared 2D CAD enhanced reader solution.
3D Detection V1
Industry-first FDA cleared 3D deep-learning Al mammography solution
3D AI Risk
Industry-first image-based 3D Al Risk solution*
ProFound Suite
4th Generation AI Detection and Cloud Deployment Option
iCAD is now part of DeepHealth
Advancing breast cancer screening and diagnosis technologies worldwide
Empowering breakthroughs in care by unlocking the value of imaging
DeepHealth is a global leader in AI-powered health informatics for real-world settings. Our solutions address both clinical and operational challenges that arise in complex, high-volume care settings, streamlining the entire workflow to ease the burden on providers and enable a more seamless experience – for care teams and patients.
Book a demo
Transforming population health with AI-powered diagnostic screening programs
Explore our visionCould healthcare begin before illness ever showed up? Rather than waiting for patients to experience symptoms, what if care started with prevention, early detection, and access to critical diagnostic tools?
Finding and treating diseases, like breast cancer, at earlier stages increases survival rates.1 Screening healthy people helps make early detection more possible. By expanding screening for a range of diseases, more people would have the chance to stay healthy longer—and this shift has the potential to significantly transform population health.
Population Health Suite of Solutions
Orchestrate and scale high-volume cancer screening and disease assessment programs
Find out moreLearn more
RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer
Los Angeles, CA and Nashua, NH – April 15, 2025, RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, and iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in providing clinically proven AI-powered breast health solutions, announced today that they have entered into a definitive merger agreement under which RadNet will acquire iCAD in an all stock transaction.
Reimagining population health: Fighting disease before it takes hold
Leading the AI revolution in healthcare
In an era where technology is reshaping healthcare, DeepHealth stands at the forefront. Kees Wesdorp, President and CEO of DeepHealth, shares his insights on the pivotal role of artificial intelligence (AI) and advanced informatics in revolutionizing imaging-based care for real-world impact.
1) American Cancer Society. Breast Cancer Screening Guidelines, December 2023. Available on the https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. (Accessed July 16, 2025)
Disclaimers: ProFound Detection V4 is FDA Cleared. ProFound AI V3 and PowerLook Density Assessment are FDA Cleared, CE Marked, and Health Canada Licensed. ProFound AI Risk is CE Marked and Health Canada Licensed, is not FDA Cleared, and is only available in the US for investigational use. Products may not be available in all geographies.